LSTA
Lisata Therapeutics, Inc.·Healthcare
5.01
0.200%(+0.01)
Market ClosedLast Updated: — ET
52W L: $1.8152W H: $5.07
LSTA NEWS
businesswire.com
Mar 26
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in submitting an amicus brief in support of the defendant lenders in a misguided antitrust case filed by Optimum Communications, Inc. The complaint, one of the first of its kind, is an attempt to apply traditional antitrust principles to “Cooperation Agreements”, which have grown increasingly common.
proactiveinvestors.com
Mar 9
Lisata Therapeutics to be acquired by Kuva Labs
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will launch a tender offer to purchase all outstanding Lisata shares for $5 per share in cash at closing, plus one contingent value right (CVR) per share.
prnewswire.com
Mar 9
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, March 9, 2026 /PRNewswire/ -- Ademi LLP is investigating Lisata (NASDAQ: LSTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Kuva Labs Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
proactiveinvestors.com
Mar 9
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other...
feeds.benzinga.com
Mar 9
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.
globenewswire.com
Mar 6
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
